Valeant CEO Michael Pearson said a possible revised stock and cash bid would be worth more than $200 per share, assuming that Valeant’s stock rises, and would include more cash. Allergan stock was up 1.7 percent at $180.45. Valeant’s third-quarter results were keenly anticipated for their potential impact on Valeant’s bid for Allergan, maker of anti-wrinkle injection Botox. Unlike most quarters in which, according to critics, one-time charges related to acquisitions obscure Valeant’s performance, the company made few deals as it stalked Allergan.